---
document_datetime: 2025-12-02 06:54:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dimethyl-fumarate-mylan-0.html
document_name: dimethyl-fumarate-mylan-0.html
version: success
processing_time: 0.1059951
conversion_datetime: 2025-12-24 03:08:48.700756
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dimethyl fumarate Mylan

[RSS](/en/individual-human-medicine.xml/67552)

##### Revoked

This medicine's authorisation has been revoked

dimethyl fumarate Medicine Human Revoked

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dimethyl fumarate Mylan](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 13 December 2023, the European Commission revoked the marketing authorisation of Dimethyl fumarate Mylan (dimethyl fumarate) in the European Union (EU). Dimethyl fumarate Mylan was a generic medicine of Tecfidera.

The marketing authorisation holder for the medicine was Mylan Ireland Limited. The revocation of the marketing authorisation was necessary in order to implement the judgment of the Court of Justice of 16 March 2023 in Commission and Others v Pharmaceutical Works Polpharma, Cases C-438/21 P to C-440/21 P.

It follows from that judgment that the marketing authorisation for Dimethyl fumarate Mylan was submitted at a point in time when the regulatory data protection period of the reference product (Tecfidera) had not expired. Further information in relation to the revocation of Dimethyl fumarate Mylan may be found in the Commission Implementing Decision revoking the marketing authorisation, which is available on the Union Register of medicinal products for human use.

Dimethyl fumarate Mylan was granted marketing authorisation in the EU on 13 May 2022 for treatment of relapsing remitting multiple sclerosis (RRMS).

Following a new application by the company, a marketing authorisation was granted by the European Commission on 22 April 2024.

Dimethyl fumarate Mylan : EPAR - Medicine Overview

Reference Number: EMEA/H/C/005956

English (EN) (210.35 KB - PDF)

**First published:** 22/12/2023

[View](/en/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-280)

български (BG) (292.87 KB - PDF)

**First published:**

22/12/2023

[View](/bg/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_bg.pdf)

español (ES) (247.37 KB - PDF)

**First published:**

22/12/2023

[View](/es/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_es.pdf)

čeština (CS) (283.91 KB - PDF)

**First published:**

22/12/2023

[View](/cs/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_cs.pdf)

dansk (DA) (235.18 KB - PDF)

**First published:**

22/12/2023

[View](/da/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_da.pdf)

Deutsch (DE) (249.58 KB - PDF)

**First published:**

22/12/2023

[View](/de/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_de.pdf)

eesti keel (ET) (223.98 KB - PDF)

**First published:**

22/12/2023

[View](/et/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_et.pdf)

ελληνικά (EL) (298.74 KB - PDF)

**First published:**

22/12/2023

[View](/el/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_el.pdf)

français (FR) (250.47 KB - PDF)

**First published:**

22/12/2023

[View](/fr/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_fr.pdf)

hrvatski (HR) (264.29 KB - PDF)

**First published:**

22/12/2023

[View](/hr/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_hr.pdf)

italiano (IT) (242.84 KB - PDF)

**First published:**

22/12/2023

[View](/it/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (288.21 KB - PDF)

**First published:**

22/12/2023

[View](/lv/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (268.82 KB - PDF)

**First published:**

22/12/2023

[View](/lt/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_lt.pdf)

magyar (HU) (276.11 KB - PDF)

**First published:**

22/12/2023

[View](/hu/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_hu.pdf)

Malti (MT) (279.51 KB - PDF)

**First published:**

22/12/2023

[View](/mt/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_mt.pdf)

Nederlands (NL) (246.42 KB - PDF)

**First published:**

22/12/2023

[View](/nl/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_nl.pdf)

polski (PL) (284.75 KB - PDF)

**First published:**

22/12/2023

[View](/pl/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_pl.pdf)

português (PT) (242.11 KB - PDF)

**First published:**

22/12/2023

[View](/pt/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_pt.pdf)

română (RO) (275.29 KB - PDF)

**First published:**

22/12/2023

[View](/ro/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_ro.pdf)

slovenčina (SK) (274.21 KB - PDF)

**First published:**

22/12/2023

[View](/sk/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_sk.pdf)

slovenščina (SL) (264.77 KB - PDF)

**First published:**

22/12/2023

[View](/sl/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_sl.pdf)

Suomi (FI) (242.03 KB - PDF)

**First published:**

22/12/2023

[View](/fi/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_fi.pdf)

svenska (SV) (234.61 KB - PDF)

**First published:**

22/12/2023

[View](/sv/documents/overview/dimethyl-fumarate-mylan-epar-medicine-overview_sv.pdf)

Dimethyl fumarate Mylan : EPAR - Risk management plan summary

English (EN) (137.4 KB - PDF)

**First published:** 22/12/2023

[View](/en/documents/rmp-summary/dimethyl-fumarate-mylan-epar-risk-management-plan-summary_en.pdf)

## Product information

Dimethyl fumarate Mylan : EPAR - Product Information (no longer authorised)

English (EN) (2.04 MB - PDF)

**First published:** 22/12/2023

[View](/en/documents/product-information/dimethyl-fumarate-mylan-epar-product-information_1-en.pdf)

[Other languages (24)](#file-language-dropdown-105)

български (BG) (2.83 MB - PDF)

**First published:**

22/12/2023

[View](/bg/media/55066)

español (ES) (2.24 MB - PDF)

**First published:**

22/12/2023

[View](/es/media/55066)

čeština (CS) (2.71 MB - PDF)

**First published:**

22/12/2023

[View](/cs/media/55066)

dansk (DA) (2.17 MB - PDF)

**First published:**

22/12/2023

[View](/da/media/55066)

Deutsch (DE) (2.37 MB - PDF)

**First published:**

22/12/2023

[View](/de/media/55066)

eesti keel (ET) (2.34 MB - PDF)

**First published:**

22/12/2023

[View](/et/media/55066)

ελληνικά (EL) (3.05 MB - PDF)

**First published:**

22/12/2023

[View](/el/media/55066)

français (FR) (2.61 MB - PDF)

**First published:**

22/12/2023

[View](/fr/media/55066)

hrvatski (HR) (2.41 MB - PDF)

**First published:**

22/12/2023

[View](/hr/media/55066)

íslenska (IS) (2.18 MB - PDF)

**First published:**

22/12/2023

[View](/is/media/55066)

italiano (IT) (2.12 MB - PDF)

**First published:**

22/12/2023

[View](/it/media/55066)

latviešu valoda (LV) (2.56 MB - PDF)

**First published:**

22/12/2023

[View](/lv/media/55066)

lietuvių kalba (LT) (2.9 MB - PDF)

**First published:**

22/12/2023

[View](/lt/media/55066)

magyar (HU) (2.52 MB - PDF)

**First published:**

22/12/2023

[View](/hu/media/55066)

Malti (MT) (2.85 MB - PDF)

**First published:**

22/12/2023

[View](/mt/media/55066)

Nederlands (NL) (2.25 MB - PDF)

**First published:**

22/12/2023

[View](/nl/media/55066)

norsk (NO) (2.01 MB - PDF)

**First published:**

22/12/2023

[View](/no/media/55066)

polski (PL) (2.51 MB - PDF)

**First published:**

22/12/2023

[View](/pl/media/55066)

português (PT) (2.17 MB - PDF)

**First published:**

22/12/2023

[View](/pt/media/55066)

română (RO) (2.59 MB - PDF)

**First published:**

22/12/2023

[View](/ro/media/55066)

slovenčina (SK) (2.67 MB - PDF)

**First published:**

22/12/2023

[View](/sk/media/55066)

slovenščina (SL) (2.45 MB - PDF)

**First published:**

22/12/2023

[View](/sl/media/55066)

Suomi (FI) (2.28 MB - PDF)

**First published:**

22/12/2023

[View](/fi/media/55066)

svenska (SV) (2.26 MB - PDF)

**First published:**

22/12/2023

[View](/sv/media/55066)

13/12/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dimethyl fumarate Mylan : EPAR - All authorised presentations

English (EN) (123 KB - PDF)

**First published:** 22/12/2023

[View](/en/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-989)

български (BG) (157.75 KB - PDF)

**First published:**

22/12/2023

[View](/bg/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_bg.pdf)

español (ES) (130.87 KB - PDF)

**First published:**

22/12/2023

[View](/es/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (130.8 KB - PDF)

**First published:**

22/12/2023

[View](/cs/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (126.12 KB - PDF)

**First published:**

22/12/2023

[View](/da/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (127.77 KB - PDF)

**First published:**

22/12/2023

[View](/de/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (127.08 KB - PDF)

**First published:**

22/12/2023

[View](/et/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (135.4 KB - PDF)

**First published:**

22/12/2023

[View](/el/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_el.pdf)

français (FR) (130.85 KB - PDF)

**First published:**

22/12/2023

[View](/fr/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (129.63 KB - PDF)

**First published:**

22/12/2023

[View](/hr/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (129.44 KB - PDF)

**First published:**

22/12/2023

[View](/is/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (132.43 KB - PDF)

**First published:**

22/12/2023

[View](/it/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (131.86 KB - PDF)

**First published:**

22/12/2023

[View](/lv/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (127.96 KB - PDF)

**First published:**

22/12/2023

[View](/lt/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (148.49 KB - PDF)

**First published:**

22/12/2023

[View](/hu/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (112.51 KB - PDF)

**First published:**

22/12/2023

[View](/mt/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (134.63 KB - PDF)

**First published:**

22/12/2023

[View](/nl/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (126.73 KB - PDF)

**First published:**

22/12/2023

[View](/no/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_no.pdf)

polski (PL) (134.46 KB - PDF)

**First published:**

22/12/2023

[View](/pl/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_pl.pdf)

português (PT) (125.79 KB - PDF)

**First published:**

22/12/2023

[View](/pt/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_pt.pdf)

română (RO) (126.05 KB - PDF)

**First published:**

22/12/2023

[View](/ro/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (135.46 KB - PDF)

**First published:**

22/12/2023

[View](/sk/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (131.65 KB - PDF)

**First published:**

22/12/2023

[View](/sl/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (126.81 KB - PDF)

**First published:**

22/12/2023

[View](/fi/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (125.26 KB - PDF)

**First published:**

22/12/2023

[View](/sv/documents/all-authorised-presentations/dimethyl-fumarate-mylan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dimethyl fumarate Mylan Active substance dimethyl fumarate International non-proprietary name (INN) or common name dimethyl fumarate Therapeutic area (MeSH) Multiple Sclerosis, Relapsing-Remitting Anatomical therapeutic chemical (ATC) code L04AX07

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Dimethyl fumarate Mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

## Authorisation details

EMA product number EMEA/H/C/005956

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Mylan Ireland Limited

Unit 35/36

Opinion adopted 24/02/2022 Marketing authorisation issued 13/05/2022 Revocation of marketing authorisation 13/12/2023 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dimethyl fumarate Mylan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (235.66 KB - PDF)

**First published:** 22/12/2023

[View](/en/documents/procedural-steps-after/dimethyl-fumarate-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf-0)

## Initial marketing authorisation documents

CHMP summary of opinion for Dimethyl fumarate Mylan

English (EN) (166.93 KB - PDF)

**First published:** 22/12/2023

[View](/en/documents/smop-initial/chmp-summary-opinion-dimethyl-fumarate-mylan_en.pdf)

Dimethyl fumarate Mylan : EPAR - Public Assessment Report

English (EN) (4.73 MB - PDF)

**First published:** 22/12/2023

[View](/en/documents/assessment-report/dimethyl-fumarate-mylan-epar-public-assessment-report_en.pdf)

#### News on Dimethyl fumarate Mylan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022) 25/02/2022

**This page was last updated on** 22/12/2023

## Share this page

[Back to top](#main-content)